OOIR: Observatory of International Research

Papers

(The median citation count of Journal of Thoracic Oncology is 0. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-02-01 to 2025-02-01.)

Article	Citations
Meeting Announcements	661
Better Together: Advancing Tobacco Use Treatment and Lung Cancer Screening	346
In This Issue/Research Watch/News in Brief	318
Board of Directors	303
FP14.05 LIBRETTO-431: Selpercatinib in Treatment-Naïve Patients with RET Fusion-Positive Non-Small Cell Lung Cancer (NSCLC).	268
Do We Really Understand the Relationship Between Expression of ACE2 and Coronavirus Disease 2019 Lung Pathophysiology?	209
Reply to Kus and Aktas	198
New Pulmonary Infiltrates Observed on Computed Tomography-Based Image Guidance for Radiotherapy Warrant Diagnostic Workup for Coronavirus Disease 2019	194
P76.95 Brief Report: Immunochemotherapy in Five Patients with EGFR Exon 20 Insertion Advanced Lung Adenocarcinoma	189
Editorial Commentary: Baseline Radiomic Signature to Estimate Overall Survival in Patients With NSCLC	185
Erratum	185
Board of Directors	158
“Tumor-free survival” Does Not Outweigh the Adverse Effects of Anti-EGFR Therapy and Chemotherapy in Patients With NSCLC	157
A Response to the Letter to the Editor: “Prognostic Factors for Survival After Thymoma Distant Recurrence Resection”	152
Table of Contents	146
Editorial Comment: Validation Study for the N Descriptor of the Newly Proposed 9th Edition of the TNM Staging System Proposed by the International Association for the Study of Lung Cancer	145
Tobacco News Update—From the IASLC Tobacco Control Committee	144
Letter Regarding “Clinical Utility of Circulating Tumor DNA in Patients With Advanced KRASG12C-Mutated NSCLC Treated With Sotorasib”	142
P65.04 Tracking circRNAs in Lung Adenocarcinoma Samples as Promising Biomarkers for Cancer Detection using the NanoString nCounter®	141
Response to Commentary on “EGFR Oncogenic Mutations in NSCLC Impair Macrophage Phagocytosis and Mediate Innate Immune Evasion Through Up-Regulation of CD47”	138
Prevalence of EGFR Mutations in Patients With Resected Stages I to III NSCLC: Results From the EARLY-EGFR Study	136
Board of Directors	116
Socioeconomic Inequalities in Novel NSCLC Treatments During the Era of Tumor Biomarker-Guided Therapy: A Population-Based Cohort Study in a Publicly Funded Health Care System	112
The HILUS-Trial—a Prospective Nordic Multicenter Phase 2 Study of Ultracentral Lung Tumors Treated With Stereotactic Body Radiotherapy	111
In This Issue	108

Meeting Announcements	104
A Response to the Letter to the Editor: Safety Implications of Switching Pembrolizumab Dosage From 200 mg Every 3 Weeks to 400 mg Every 6 Weeks in Patients With Advanced NSCLC	95
Table of Contents	94
Suggestions for Improving the Comprehensive Characterization of Lung Pleomorphic Carcinoma	91
Board of Directors	91
Future Radiation Oncology: The Role of Personalization and Standardization in Stereotactic Body Radiotherapy	91
The International Association for the Study of Lung Cancer Mesothelioma Staging Project: Proposals for Revisions of the “T” Descriptors in the Forthcoming Ninth Edition of the TNM Classification for P	90
Treatment of Leptomeningeal Metastases: New Hammer, the Same Nail	90
Table of Contents	89
In This Issue	89
Editorial Board	88
PP01.67 Evaluating immune-related adverse events (irAEs) in a real-world cohort with lung cancer receiving immunotherapy	87
PP01.112 Treatment Patterns and Outcomes in Second-Line Advanced NSCLC Treated After Prior Platinum Chemotherapy and Immunotherapy Combination Therapy: A Real-World Study	86
PP01.109 Concordance of Breast Density Between Low-Dose CT and Mammogram	82
PP01.18 Real-world evaluation of racial and socioeconomic disparities in patients with NSCLC treated with immunotherapy	81
OA01.01 Beamion LUNG-1: Phase Ia/b Trial of HER2 Tyrosine Kinase Inhibitor Zongertinib (BI 1810631) in Patients with HER2 Aberration-Positive Solid Tumors	78
PP01.172 It's Never Too Late To Quit	75
PPD01.02 Repotrectinib in Patients With ROS1 Fusion-Positive (ROS1+) NSCLC: Update From the Pivotal Phase 1/2 TRIDENT-1 Trial	75
PP01.85 A Phase 2/3 Study of Fianlimab, Cemiplimab, plus Chemotherapy Versus Cemiplimab plus Chemotherapy in First-Line Advanced Non-Small Cell Lung Cancer	75
PP01.40 Treatment Patterns and Survival Outcomes of Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer Survival at a Safety-Net Hospital	73
PP01.117 Real-World Effectiveness and Safety Profile of Lurbinectedin and Other Second-Line Treatments in Small Cell Lung Cancer	73
PP01.101 Estimated Cost of Adverse Events and Surgery for Resectable Non-Small Cell Lung Cancer Patients Receiving Neoadjuvant Nivolumab Plus Platinum-Doublet Chemotherapy	73
PP01.65 Efficacy and Safety of Dose-Escalated Alectinib in Patients with Metastatic ALK-positive NSCLC and CNS Relapse on Standard Dose Alectinib	72
PPD01.06 Sacituzumab Govitecan + Pembrolizumab in 1L Metastatic Non–Small Cell Lung Cancer: Preliminary Results of the EVOKE-2 Study	70
PP01.06 Role of number of pathologic N2 stations for future AJCC lung cancer staging versions	67
PP01.23 Plasma cell-free RNA PD-L1 or Tissue PD-L1 Protein Expression and Immunotherapy Outcomes in Advanced Non-Small Cell Lung Cancer	67
PP01.119 Real-World Use of Lurbinectedin in Patients with Small Cell Lung Cancer: Jazz EMERGE 402 Updated Analysis	66
PP01.136 Understanding Experiences of Cancer-Related Fatigue in Patients with Lung Cancer After Their Cancer Treatment: A Qualitative Content Analysis	66
PP01.169 Promotion of Low-Dose Computed Tomography Screening and Blood Biomarkers in Minority Communities for Early Detection of Lung Cancer in Northern Illinois	65
PP01.74 LiquidHALLMARK detects more tissue-confirmed guideline-recommended biomarkers than Guardant360 for lung cancer: a prospective multicenter study	63
PP01.26 Proprietary vs Open-Source Radiomic Platform for Lung Cancer Diagnosis	63
PP01.90 Real-world Demographics, Clinical Characteristics, Treatment Patterns and Clinical Outcomes for US Patients with Limited-Stage SCLC (LS-SCLC)	62
PP01.20 Hospitalization patterns for immune-related adverse events in patients with NSCLC treated with immunotherapy vs chemo-immunotherapy	61
PP01.108 Trial in Progress: Shared Decision-Making Encounter Tool for Adjuvant Treatment of Lung Cancer: Randomized Control Trial	59
EP08.02-076 Efficacy and Safety Evaluations of Anlotinib in Patients with Advanced Non-small Cell Lung Cancer Treated with Bevacizumab	58
PP01.135 Outcomes and Treatment Patterns for Recurrence following Concurrent Chemoradiation and Consolidation Immunotherapy in Unresectable Stage III NSCLC: A Multi-Center Study	58
EP08.02-061 Treatment Sequences in ALK-rearranged Non-small Cell Lung Cancer; What Happens in the Real World?	57
P76.97 Exploration of the Gene Fusion Landscape of Lung Cancer in a Chinese Retrospective Analysis	57
P76.88 Real-World Data of Osimertinib in Patients with Metastatic EGFRm+ NSCLC who Progressed on First-Line EGFR TKIs	57
P76.86 WITHDRAWN	57
MA07.01 How Lung Cancer Patients Perceive their Treating Doctors and Engage in medical decision-making: Lessons from Project PRIORITY	55
P78.01 Nivolumab in Second Line Non-Small Cell Lung Cancer – Comparing Real-World Outcomes in England to CheckMate (CM) 017 and 057	55
P78.06 Dynamic Risk Prediction for Disease Control With Nivolumab in Advanced or Recurrent Non-Small Cell Lung Cancer Patients (NewEpoch)	54
P78.03 Camrelizumab Umbrella Trial Based on PD-L1 Expression: OS and PFS2 in Pre-Treated Advanced NSCLC	54
P76.94 Survival Analyses and Molecular Predictors of Outcomes in Patients Treated with Osimertinib for Metastatic NSCLC Harboring EGFR Mutation	53
P76.93 The Efficacy of Second-Line Osimertinib Plus Bevacizumab in Chinese Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)	53
P78.04 Efficacy and Safety Analysis of Atezolizumab Monotherapy in Patients With Non-Small Cell Lung Cancer	53
EP08.02-077 Two Phase III Trials of Aumolertinib Plus Chemotherapy for NSCLC with EGFR and Concomitant non-EGFR Driver Genes /Tumor Suppressor Genes	52
P54.05 Stereotactic Radiotherapy for Brain Metastases in Patients With Lung Cancer: Cyberknife Experience	52
EP08.02-080 EGFR Testing Practices, Treatment Choice and Clinical Outcomes in Advanced NSCLC in a Real-World Setting	51

P56.01 Semiquantitative Assessment of Tumor Spread Through Air Spaces in a Historic Cohort of Lung Adenocarcinomas Following Open Surgical Resection	50
P53.08 Concomitant Fibrates and Immunotherapy in Non-Small Cell Lung Cancer Patients in the Veterans Health Administration	50
P54.04 Detecting Elevated Risk of Diminished Quality of Life Among Lung Cancer Patients by Using Wearable Devices	50
EP08.02-088 Mutational Status of KRAS, STK11 and CDKN2A Genes as Predictors of Response to Antiangiogenic Agents in Non-small Cell Lung Cancer Patients	50
EP08.02-043 The Current State of Biomarker Testing in Lung Cancer as Seen by Health Care Providers	48
EP08.02-097 Prevalence, Clinical Characteristics and Survival of Patients With Brain Metastases and KRAS Mutation Lung Cancer in Argentina	48
FP10.04 RESILIENT Part 1: Safety and Efficacy of Second-Line Liposomal Irinotecan in Patients with Small Cell Lung Cancer	48
P76.43 Co-occurring genomic alterations and treatment outcomes in patients with EGFR exon 20 insertion positive NSCLC	47
P76.35 Genomic Characteristics and Prognosis of Concomitant with EGFR Copy Numbers Variations in EGFR Mutated Lung Cancer Patients	46
P48.03 Spectrum of Resistance Mechanisms to First, Second and Third Generation Tyrosine Kinase Inhibitors in EGFR Mutant NSCLC Patients	46
P48.15 EGFR Mutated Non-Small Cell Lung Cancer Treatment Pathway – What Is the Best Way?	46
EP08.02-050 A Retrospective Study of Aumolertinib in Combination with Bevacizumab for EGFR-mutated NSCLC with the Presence of Leptomeningeal Metastasis	46
P48.08 The Efficacy and Clinical Survival Outcome of Different First-Line Treatments in EGFR Mutant Non-Small Cell Lung Cancer With Brain Metastases	46
P76.76 EGFR Tyrosine Kinase Inhibitors in Patients with Non-Small Cell Lung Cancer and the Role of Diabetes Mellitus and Metformin	45
P76.54 Prognostic Value of Radiotherapy Pattern for Late-Stage Epidermal Growth Factor Receptor (EGFR) Mutant Lung Adenocarcinomas	44
FP12.08 The Survival Impact of Circulating T Regulatory Cells Subsets in Patients with Untreated Lung Cancer	44
FP14.01 WITHDRAWN	44
MA05.03 Differential Frequency of Blood Immune Cells as Biomarkers for Risks Assessment in bioMILD Lung Cancer Screening Trial	44
P51.01 Tepotinib Plus an EGFR TKI in Patients with EGFR-mutant NSCLC and Resistance to EGFR TKIs Due to MET Amplification (METamp)	44
FP14.13 Molecular Characterisation and Clinical Outcomes in RET Rearranged Non-Small Cell Lung Cancer (NSCLC)	43
MA05.11 Effect of Lowering the Starting Age for Lung Cancer Screening by Low-Dose Computed Tomography Among Women: A Harm-Benefit Analysis	43
EP08.02-063 SANOVO: A Phase 3 Study of Savolitinib or Placebo in Combination with Osimertinib in Patients with EGFR-mutant and MET Overexpressed NSCLC	43
P50.06 First-Line Therapy in NSCLC harbouring EGFR or HER2 Exon 20 Insertion Mutation. Hunting for the Best Candidate	42
EP08.02-130 Tegavivint Exhibits Antitumor Activity and Modulates Macrophage Phenotype in the Non-small Cell Lung Cancer Tumor Microenvironment	41
P84.21 Treatment with Alectinib after Crizotinib-Induced Hepatitis in an ALK-Rearranged Advanced NSCLC-Patient	41
P85.03 PD-L1 Expression and Efficacy of Immunotherapy in Japanese Patients with NSCLC Harboring MET Exon 14 Skipping Mutation.	41
P86.15 Osimertinib Real-World Experience in EGFR T790M Positive Locally Advanced or Metastatic NSCLC in Taiwan	41
P85.04 Capmatinib in Patients with METex14-Mutated Non-Small Cell Lung Cancer: GEOMETRY Mono-1 Asian Subgroup Analysis	40
P87.01 Higher Dose Alectinib for Advanced RET+ NSCLC: Results from the RET+ Cohort of the Blood First Assay Screening Trial (BFAST)	40
P85.01 Activity of Tepotinib in Brain Metastases (BM): Preclinical and Clinical Data in MET Exon 14 (METex14) Skipping NSCLC	40
EP08.02-167 Diverse Effects of Radiotherapy for Osimertinib Acquired Resistance Non-small Cell Lung Cancer: Gene Matters	39
EP08.02-128 Long Term Efficacy of SNK01 Plus Pembrolizumab for NSCLC: Expanded Observation from a Phase I/II A Randomized Controlled Trial	39
P86.23 Clinical Efficacy Analysis of Apatinib as a Second-Or Further-Line Treatment in Patients With Advanced NSCLC	38
P59.18 Evaluation of ROS1 Expression in a Large Cohort of Early Stage Lung Cancer	38
P59.01 Clinical Characteristics of Patients With MET Amplification-Positive NSCLC After EGFR-TKI Therapy	38
MA12.03 Prognostic Value of Clinical Staging According to TNM in SCLC Patients; A Real-World SEER Database Analysis.	37
EP10.01-002 The Effect of Group Rehabilitation Training in the Ward on the Psychological Status and Quality of Life of Lung Cancer Patients	36
P60.13 MYLUNG Consortium: Molecularly Informed Lung Cancer Treatment in a Community Cancer Network. Pragmatic Prospective RWR Study	36
P88.04 Successful Low-Dose Treatment for Patients with ROS1-Rearranged NSCLC who Developed Crizotinib-Related Heart Failure.	36
P36.12 WITHDRAWN	36
OA11.06 IMpower133: Exploratory Analysis of Maintenance Therapy in Patients With Extensive-Stage Small-Cell Lung Cancer	36
EP10.01-016 Cachexia’s Impact on Immunotherapy Dose Reduction, Treatment Discontinuation, and Survival: a Systematic Review	36
EP08.04-003 A Simple Clinical Prediction Score to Determine Response to First Line Chemotherapy Treatment in Advanced Non-Small Cell Lung Cancer Patients	36
P61.05 Time to Loosen Up: Liberalizing Lung Cancer Screening Guidelines Might Save More Lives	35
P05.09 Thoracic Re-Irradiation Dose Constraints for Late Lung Fibrosis: Preliminary Modelling Results	35
P02.15 Intraparenchymal Blood Patch after CT Guided Biopsy of Lung and Mediastinal Lesions Reduces the Risk of Pneumothorax	35
EP08.02-046 Activity of OsimeRTInib in NSCLC with Uncommon EGFR Mutations: Retrospective Observational Multicenter Study (ARTICUNO)	34
P76.06 A Novel EGFR G724S and R776H Rare Co-Mutation Response to Afatinib in a Patient With Lung Adenocarcinoma	34
FP07.10 Circulating Tumor DNA Analysis in NSCLC with MET exon 14 Skipping Alterations	34
FP07.17 The Impact of Blood Based Host Immune Profile to Identify Aggressive Early Stage NSCLC	34
FP07.07 Value of the Lung Immune Prognostic Index (LIPI) As a Prognostic Tool for Real-World Patients Treated for Mutation-Positive Metastatic NSCLC	34
69P VMAT based SBRT in early stage NSCLC: Outcomes and toxicities	34
P47.06 TROPION-Lung04: Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab and Platinum-Based Chemotherapy in Advanced NSCLC	33
P76.48 A CT-Based Radiomic Feature Predicts EGFR Mutation and Response to Targeted Therapy in NSCLC	33
Outcomes by ALK Status (Immunohistochemistry or Fluorescence In Situ Hybridization) in ALEX	33
PP01.30 Integration of molecular cancer classification and NGS to identify patients with cancer of unknown primary (CUP) and other unclear diagnoses eligible for KRAS inhibitors	33
Lung Cancer in Colombia	32
EGFR Tyrosine Kinase Inhibitor Sequencing Revisited: From the Revival of Old Tools to the Integration of New Agents	32
Beyond Personalized to “Tumoralized” Therapy	32
Safety Implications of Switching Pembrolizumab Dosage From 200 mg Every 3 Weeks to 400 mg Every 6 Weeks in Patients With Advanced NSCLC	32
Editorial Board	32
Identification of a Novel MET Exon 14 Skipping Variant in Lung Adenocarcinoma Sensitive to Crizotinib Treatment	32
FP03.03 Clinical Activity of BMS-986012, an Anti–Fucosyl-GM1 Monoclonal Antibody, Plus Nivolumab in Small Cell Lung Cancer	32
In Response to Continuation of Lorlatinib Beyond Progressive Disease	32
Hippocampal Avoidance Prophylactic Cranial Irradiation for SCLC	32
Real-World Evidence of the Association Between Rheumatoid Arthritis and Lung Cancer	31
Table of Contents	31
FP13.03 IMpower110: Updated OS Analysis of Atezolizumab vs Platinum-Based Chemotherapy as First-Line Treatment in PD-L1–Selected NSCLC	31
Bintrafusp Alfa in the Second-Line Treatment of Patients With NSCLC	31
Anti–Vascular Endothelial Growth Factor/Programmed Cell Death Protein 1 Bispecific Antibodies: Using Nunchucks to Fight an Old Adversary	31
Response to Letter to the Editor From Binghao Zhao et al	30
Personalized Cytokine-Directed Therapy With Tocilizumab for Refractory Immune Checkpoint Inhibitor–Related Cholangiohepatitis	30
ES28.03 Mechanisms of Resistance to KRAS G12C Inhibitors	30
ES13.06 Developing a Care Board	30
Board of Directors	30
P49.01 Drug Holiday Based on Minimal Residual Disease Status After Local Therapy Following EGFR-TKI Treatment for Patients With Advanced NSCLC	30
P14.01 Phase 3 Study of First-Line Pembrolizumab ± Vibostolimab (anti-TIGIT) in Patients With PD-L1‒Positive Metastatic NSCLC	30
OA01.02 Impact of COVID-19 Outbreak on Lung Cancer Diagnosis and Continuum of Care: Data From an Italian Multicenter Study	30
P40.13 Lung Cancer 5-Year Survival in Croatia - Our Experience	30
Pitfalls in Molecular Testing and the Added Value of the Cancer Research Biomedical Community	30

The Anti–Programmed Cell Death Protein-1/ Programmed Death-Ligand 1 Me-Too Drugs Tsunami: Hard To Be Millennials Among Baby Boomers	30
Table of Contents	30
P55.02 WITHDRAWN	30
ES13.03 Managing the Psychological Needs of Patients in a Screening Service	29
P63.02 CDK9 Mediate Lung Adenocarcinoma A549 Cell Brain Metastasis in Murine Model	29
P65.02 LINC01234 acts as an Oncogenic lncRNA that Interacts with HNRNPA2B1 and Regulates miR-106b Biogenesis	29
ES22.06 Early Integration of Palliative Care Is the Answer to Improving Quality of Life	29
ES16.04 Campaigning for Lung Cancer Screening - A Tool for Advocates	29
ES23.01 Pro-Con: Non-Anatomic Parameters Should Be Included Into Current TNM Classification (Genetic, Molecular, Histology, etc)	29
P34.05 Three Birds, One Stone: IVIG Use in Hypogammaglobulinemia, Checkpoint Inhibitor Pneumonitis, and Persistent COVID-19	28
P57.04 Mutations of DNA Damage Repair Genes in Lung Adenocarcinoma and Their Association with Actionable Alterations	28
PL04.04 Implementing New Paradigms for Delivering Radiation Therapy in the Clinic	28
P58.03 Investigation on the Role of Methylation in Field Cancerization of Non-Small Cell Lung Cancer	28
P40.14 Efficacy and Safety of Endostar Combined With Camrelizumab and Chemotherapy in Treatment of Advanced NSCLC: A Multi-Center Retrospective Study	28
P39.01 Long-Term Outcomes and Characteristics of Unresectable Locally Advanced Thymic Malignancies	28
P59.06 Mutational Landscape and Differential Expression Analysis of Transcription Factors in Non-Small Cell Lung Cancer	28
PL05.09 Cancer Treatment in Asia - What is Available, and Is It Effective Enough?	28
PL03.06 Improving Outcomes with Immunotherapy: Lessons from Other Diseases	28
P34.04 Chemo-Immunotherapy in Non-Small Cell Lung Cancer (NSCLC) – Real World Data from a Tertiary Oncology Centre	27
P39.05 Outcomes of Videothoracoscopic Thymectomy for Treatment Large-Sized Thymomas	27
P37.01 The Results of Multimodal Treatment With Extrapleural Pneumonectomy for Female Epithelioid Malignant Pleural Mesothelioma	27
PL02.06 Patient-Directed Innovation, Research and Clinical Trials	27
P59.01 AR Mutations Defines a Unique Molecular Class of Non-Small Cell Lung Cancer in East Asian Patients	27
P36.03 Rapidly Progressed Anaplastic Carcinoma in the Anterior Mediastinum Successfully Treated With Gene-Targeted Therapy	27
P64.01 MiRNAs in Exosomes Isolated From the Blood of Non-Small Cell Lung Cancer Patients: Biomarkers for Lung Cancer Prediction and Prognosis	26
ES21.03 The Specifics of Smoking Cessation for Cancer Patients	26
P41.01 Abscopal Response Induced by Thermal Ablation in Advanced NSCLC Patients Failed From Immunotherapy: Preliminary Result From a Phase 2 Trial	26
P42.04 Prognosis Factors in Advanced Lung Cancer Patients Treated With Checkpoint Inhibitor-Based Immunotherapy	26
ES23.05 GGN Issues	25
EP08.02-006 Data from Real World to Evaluate the Efficacy of Almonertinib in EGFR-mutant NSCLC Patients	25
P45.14 Real-World Experience on Treatment of crizotinib in ALK/ROS1/MET Alterated Non-Small-Cell Lung Cancer Patients in China	25
ES30.05 Combination Therapy Approaches to Target Rare Mutations (ErbB Receptors and KRAS pG12C) in NSCLC	24
P75.10 Risk Factors for Immune-Related Adverse Events from Anti-PD-1/PD-L1 Treatment in an Asian Cohort of NSCLC Patients	24
P72.10 Prognostic Significance of IgA+ B Cells in Non-Small Cell Lung Cancer	24
EP08.02-027 T790M Detection Rate After First-Line Treatment with Bevacizumab Plus 1st or 2nd Generation EGFR-TKI in Advanced NSCLC	24
P75.01 Activity of Brigatinib in Alectinib-Resistant ALK-Positive NSCLC According to ALK Plasma Mutation Status From J-ALTA Trial	24
P72.06 NLRP4-Mediated Type I Interferon Response Benefits Immune Checkpoint Therapy Through Redirecting CD8+ T Cell Distribution in TME	24
FP01.03 Genetic Predisposition for Pre-Invasive Lung Adenocarcinoma Manifesting as Ground-Glass Nodules with Family History of Lung Cancer	24
FP07.08 A Pan-Canadian Validation Study for the Detection of EGFR-T790M Mutations Using Circulating Tumour DNA (ctDNA) from Blood	23
FP04.04 EGFR Mutations Predict Superior Survival of NSCLC Patients with Oligometastatic Disease Treated with Local Consolidative Therapy	23
ES01.02 Squamous	23
P59.07 Molecular Profiling of Human Non-Small Cell Lung Cancer by Single-Cell RNA-Seq	23
P39.04 Thymic Epithelial Tumors: The Importance of Invasive Investigation to Adequate Diagnosis	23
EP08.01-104 Baseline Tumor Size and Survival Outcomes among Patients with Advanced NSCLC treated with First-Line Immunotherapy	23
FP02.02 Real-World Outcomes Among Advanced Non-Small Cell Lung Cancer Patients Re-Treated with Immunotherapy in the US	23
P60.09 High Circulating Regulatory (FoxP3+) T Cells and TGF-β Predict the Response to Anti-PD-1 Immunotherapy in NSCLC Patients	23
P37.03 The Epidemic of Malignant Mesothelioma in China: A Prediction of Incidence During 2016-2030	23
P40.11 Trimodality Therapy Protocol in 144 Superior Sulcus Patients: Good Results Even for Extended Resections and Indications	22
EP08.02-013 Prognostic Utility of the ALI (Advanced Lung Index) in Crizotinib-Treated ALK and ROS1Fusion-Positive NSCLC	22
P45.11 Co-occurring CDKN2A/B Alteration Is Associated With Worse Survival Outcomes in Advanced ALK-Positive Non-Small Cell Lung Cancer	22
ES05.03 Radiation Oncology: Value and Innovation	22
EP08.01-110 Trial in Progress: A Phase 2 Multicenter Study (IOV-LUN-202) of Autologous Tumor-infiltrating Lymphocyte (TIL) Cell Therapy (LN-145) in mNSCLC	22
P69.01 Real-World Data of EGFR-TKI Treatment Sequence in Non-Small Cell Lung Cancer Patients in Japan	22
P70.01 Distribution of CCND1 Mutations in East Asian Patients With Non-Small Cell Lung Cancer	22
P38.02 The Prognostic Role of Neutrophil to Lymphocyte Ratio (NLR) In Lung Metastasectomy for Colorectal Cancer: A Meta-Analysis	22
P72.03 Tumor Microenvironment Disparity in Multiple Primary Lung Cancers	22
FP02.07 Predicting the Future: Using AI to Predict Treatment Outcomes in Lung Cancer	22
P59.06 Prognostic Nutritional Index in Real-World Patients Receiving Systemic Therapy for Driver Mutation-Positive Metastatic NSCLC	21
P59.04 Molecular Characterization of Unactionable EGFR Mutation in Non-Small Cell Lung Cancer	21
P57.12 Clinical and Molecular Features of Chinese Lung Cancer Patients With Germline Mismatch Repair Gene Mutations	21
P45.03 Tepotinib in Patients with MET exon 14 (METex14) Skipping NSCLC as Identified by Liquid (LBx) or Tissue (TBx) biopsy	21
P84.22 Outcomes of TKI Treatment in Patients with NSCLC Harboring Uncommon EGFR Mutations: A Real-World Study in Argentina	21
P45.05 Sequencing of PD-1 Inhibitors and TKIs in Metastatic NSCLC with MET Exon 14 Skipping Mutation May Influence Survival	21
MA01.11 CD47 Agonist Peptide PKHB1 Induced Cell Death in NSCLC via Triggering Endoplasmic Reticulum Stress	21
P81.02 Neoadjuvant PD-1/PD-L1 Immune Checkpoint Inhibitors in Solid Tumors	21
P83.03 Efficacy of Camrelizumab (SHR-1210) Plus Apatinib in Advanced NSCLC with EGFR Mutation	21
MA09.03 Comparative Effectiveness of a Lymph Node Collection Kit Versus ‘Heightened Awareness’ on Lung Cancer Surgery Quality and Outcomes	21
P84.16 Treatment Options for Patients with Brain Metastases in Oncogene-Driven Non-Small Cell Lung Cancer	21
MA02.09 Analysis of Targets for Lung Stereotactic Body Radiotherapy with Clinical Four Dimension (4D) Computed Tomography (CT)	21
P86.09 A Single-Arm Phase II Study of Anlotinib Combined with Pemetrexed plus Cisplatin as a First-Line Therapy in Advanced NSCLC	20
EP08.02-108 Osimertinib Long-Term Tolerability in Patients with EGFRm NSCLC Enrolled in the AURA Program or FLAURA Study	20
P82.02 Stereotactic Ablative Radiotherapy with Nivolumab for Early-Stage Operable Non-Small Cell Lung Cancer: a phase 2 study	20
MA12.06 A Study of the Prognosis of Patients With Limited-Stage SCLC Who Did Not Receive Prophylactic Cranial Irradiation After Chemoradiotherapy	20
MA01.09 Efficacy and Safety of Glembatumumab Vedotin in Patients With Advanced or Metastatic Squamous Cell Carcinoma of the Lung (PrECOG 0504)	20
P84.10 The Impact of 3rd-Line ALK Inhibitors in ALK Positive NSCLC in Real-World Data	20
EP08.02-100 Combination of Bevacizumab and Continuation of EGFR-TKIs in NSCLC Patients beyond Gradual Progression	20
EP08.02-091 Disease Monitoring of EGFR-mutated NSCLC Patients Treated with TKIs via EGFR Status in Circulating ctDNA	20
P56.06 Clinical Significance and Potential Function of S100A10 in Lung Adenocarcinoma	20
MA02.03 Robot-Assisted Endoscopic Airway Reconstruction Using the Newly Developed Chinese Uniportal Robotic Surgical System	19
EP08.02-119 RNA Sequencing to Characterize Pathways in EGFR-mutated Non-Small Cell Lung Cancer	19
MA03.09 Can Clinical Variables be used to Provide Better Follow up in Stereotactic Ablative Radiotherapy (SABR) Treated Lung Cancers?	19
P79.05 Phase II Randomized Trial of Neoadjuvant Pembrolizumab +/- Chemotherapy for Operable Stage IA3-IIA Non-Small Cell Lung Cancer	19
P57.08 High Performance Radiomic Classifier to Predict the Response to Immunotherapy in Advanced NSCLC	19
EP08.02-107 Molecular Biomarker Testing and Initiation of Targeted Therapy in Minority Patients with Stage IV Non-small Cell Lung Cancer	19
P84.04 HIP1-ALK Positive Non-Small-Cell Lung Cancer: Clinicopathological Characteristics and Prognosis	19
EP08.01-024 Multicenter Real Life Clinical Outcomes of PDL-1 Tested Patients with Non Small Cell Lung Cancer (NSCLC) in Turkey	18
EP08.01-056 Pemetrexed-Based Chemotherapy Plus ICIs or Bevacizumab as First-Line Strategy for Patients with Lung Adenocarcinoma in Real-World Setting	18
EP08.01-021 Phase 2 Study Evaluating Inupadenant in Combination with Chemotherapy in Adults with NSCLC who Progressed on Immunotherapy	18
EP08.01-053 PD-1 Inhibitors Plus Chemotherapy in Patients with Brain Metastasis and EGFR/ALK-positive Non-small Cell Lung Cancer after EGFR/ALK-TKIs	18
EP08.01-036 Low-dose EGFR-TKIs Directly Induce Maturation and Functional Activity of Human Dendritic Cells in an EGFR-independent manner	18
EP08.01-022 Treatment Outcomes of Second-Line Immune Modulators in Steroid Refractory/Resistant Immune Related Adverse Events	18
EP08.01-051 Clinical Characterization and Outcomes of Non Small Cell Lung Cancer with HER2 Alterations in the Era of Immunotherapy	18
MA02.06 Factors Affecting the Diagnostic Yield of Robot-Assisted Bronchoscopy for Pulmonary Lesions	18
218P Implications of the eighth edition of TNM staging system for thymoma, a single-center retrospective study	17
EP07.01-002 Surgery in Stage I-III Malignant Pleural Mesothelioma: A Surveillance, Epidemiology, and End Results (SEER)- Medicare Analysis 1995-2015	17